Rion
Amy Campbell is an accomplished regulatory affairs professional with extensive experience in the biopharmaceutical sector. Currently serving as the Sr. Director of Regulatory Affairs at Rion since April 2025, Amy has previously held leadership roles including Head of Nemolizumab Regulatory Strategy at Galderma Laboratories, L.P. from August 2019 to April 2025 and Director of Regulatory Affairs at Smith & Nephew Biotherapeutics from December 2012 to August 2019. Additional experience includes positions at Healthpoint, where roles encompassed Sr. Manager and Regulatory Affairs Manager, as well as a similar managerial role at Access Pharmaceuticals, Inc. Amy holds a B.S. in Biochemistry from Texas A&M University, completed in January 1997.
This person is not in any teams
This person is not in any offices
Rion
1 followers
Rion is a clinical-stage biotechnology company That develops exosome therapeutics. Purified Exosome ProductTM (PEPTM) from Rion is a potent, useful, and easily available regenerative medicine. Research by Rion and its scientific partners has demonstrated the potential of PEP to repair a variety of injured tissue, including tendons, muscles, andskin. The goal of Rion is to spread the use of clinically effective regenerative medicine throughout the world.